Says FY23 Group core operating income expected to grow high single digits, up from prior view of mid single digits.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Novartis Gains after Better-than-Expected Q1 Results, Raises Outlook
- Novartis presents new five-year data on Kesimpta
- Legend Biotech price target raised to $85 from $75 at BTIG
- Novartis price target raised to CHF 91 from CHF 88 at Morgan Stanley
- Novartis price target raised to CHF 85 from CHF 80 at Barclays
